Display options
Cite
Kim CM, Hwang S, Keam B, et al. Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver Cancer. 2020;9(2):182-192doi: 10.1159/000504548.
Kim, C. M., Hwang, S., Keam, B., Yu, Y. S., Kim, J. H., Kim, D. S., Bae, S. H., Kim, G. D., Lee, J. K., Seo, Y. B., Nam, S. W., Kang, K. J., Buonaguro, L., Park, J. Y., Kim, Y. S., & Wang, H. J. (2020). Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver cancer, 9(2), 182-192. https://doi.org/10.1159/000504548
Kim, Chang Min, et al. "Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker." Liver cancer vol. 9,2 (2020): 182-192. doi: https://doi.org/10.1159/000504548
Kim CM, Hwang S, Keam B, Yu YS, Kim JH, Kim DS, Bae SH, Kim GD, Lee JK, Seo YB, Nam SW, Kang KJ, Buonaguro L, Park JY, Kim YS, Wang HJ. Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker. Liver Cancer. 2020 Apr;9(2):182-192. doi: 10.1159/000504548. Epub 2020 Feb 18. PMID: 32399432; PMCID: PMC7206603.
Copy Download .nbib Format: NLM
Share it on

Liver Cancer. 2020 Apr;9(2):182-192. doi: 10.1159/000504548. Epub 2020 Feb 18.

Gene Signature for Sorafenib Susceptibility in Hepatocellular Carcinoma: Different Approach with a Predictive Biomarker.

Liver cancer

Chang Min Kim, Shin Hwang, Bhumsuk Keam, Yun Suk Yu, Ji Hoon Kim, Dong-Sik Kim, Si Hyun Bae, Gun-Do Kim, Jong Kyu Lee, Yong Bae Seo, Soon Woo Nam, Koo Jeong Kang, Luigi Buonaguro, Jin Young Park, Yun Soo Kim, Hee Jung Wang

Affiliations

  1. CbsBioscience Inc., Daejeon, Republic of Korea.
  2. Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  3. Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
  4. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Republic of Korea.
  5. Division of HBP Surgery and Liver Transplantation, Department of Surgery, Korea University College of Medicine, Seoul, Republic of Korea.
  6. Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  7. Department of Microbiology, College of Natural Sciences, Pukyong National University, Busan, Republic of Korea.
  8. Department of Internal Medicine, Incheon St. Mary's Hospital, The Catholic University of Korea, Incheon, Republic of Korea.
  9. Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Keimyung University Dong-San Medical Center, Daegu, Republic of Korea.
  10. Laboratory of Cancer Immunoregulation, Instituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale" - IRCCS, Naples, Italy.
  11. Division of Gastroenterology and Hepatology, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea.
  12. Department of Surgery, Ajou University School of Medicine, Suwon, Republic of Korea.

PMID: 32399432 PMCID: PMC7206603 DOI: 10.1159/000504548

Abstract

BACKGROUND/AIM: Uniform treatment of hepatocellular carcinoma (HCC) with molecular targeted drugs (e.g., sorafenib) results in a poor overall tumor response when tumor subtyping is absent. Patient stratification based on actionable gene expression is a method that can potentially improve the effectiveness of these drugs. Here we aimed to identify the clinical application of actionable genes in predicting response to sorafenib.

METHODS: Through quantitative real-time reverse transcription PCR, we analyzed the expression levels of seven actionable genes (

RESULTS: The responders had significantly higher TBS values than the nonresponders. With an area under the curve of 0.779, a TBS combining

CONCLUSIONS: Our findings on patient stratification based on actionable molecular subtyping potentially provide a therapeutic strategy for improving sorafenib's effectiveness in treating HCC.

Copyright © 2020 by S. Karger AG, Basel.

Keywords: Biomarker; Gene signature; Hepatocellular carcinoma; Sorafenib

Conflict of interest statement

The authors have no conflicts of interest to declare.

References

  1. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  2. Mol Cancer Ther. 2008 Oct;7(10):3129-40 - PubMed
  3. World J Gastroenterol. 2013 Oct 7;19(37):6144-55 - PubMed
  4. Lancet. 2018 Mar 31;391(10127):1301-1314 - PubMed
  5. Mol Cell Proteomics. 2014 Jun;13(6):1429-38 - PubMed
  6. World J Gastroenterol. 2018 Sep 28;24(36):4152-4163 - PubMed
  7. Lancet. 2018 Mar 24;391(10126):1163-1173 - PubMed
  8. Genes Dev. 2012 Jun 1;26(11):1131-55 - PubMed
  9. Semin Liver Dis. 2010 Feb;30(1):52-60 - PubMed
  10. Hepatology. 2013 Apr;57(4):1407-15 - PubMed
  11. Cancer Discov. 2014 Jun;4(6):730-43 - PubMed
  12. Int J Cancer. 2012 Dec 15;131(12):2961-9 - PubMed
  13. PLoS One. 2013 Jun 13;8(6):e64260 - PubMed
  14. N Engl J Med. 2004 May 20;350(21):2129-39 - PubMed
  15. Nat Rev Clin Oncol. 2010 Dec 07;8(4):200-9 - PubMed
  16. Front Mol Biosci. 2018 Aug 27;5:76 - PubMed
  17. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed

Publication Types